CHAIRMAN'S MESSAGE

OUR R&D PIPELINE AND HIGHLIGHTS

We are a research driven company and have a robust pipeline of 7 novel molecules – 2 NCEs and 5 NBEs in various stages of preclinical and clinical development. We are committed to R&D and will continue the same through consistent investments in research in order to generate intellectual property assets that will help address the unmet medical needs

Read More

STRATEGIC PRIORITIES

Glenmark has progressed into a global organisation in a short period of time. Our prudent strategic priorities have helped us become a leading research-driven, global, integrated pharmaceutical company...
Read More

CORPORATE RESPONSIBILITY

Our operations are conducted in a manner that is ethical, transparent, proactive, environmentally conscious and sensitive to all our stakeholders. We continuously strive to enrich the lives of the people...
Read More

OUR PEOPLE

At Glenmark, we strongly believe in the power of people who consistently fuel our growth. We nurture talent and provide learning and development opportunities to ensure capability building...
Read More

OUR GLOBAL ASSETS

Glenmark's commitment to uncompromising, world-class quality standards is reected in its state-of-the-art manufacturing facilities located across the globe. Glenmark has 17 manufacturing facilities, world over, which are approved by various regulatory bodies such as the US FDA, UK MHRA, WHO-GMP, Canadian TPD, South African MCC and ANVISA of Brazil.

Read More

0
Nations with our offices

0
Manufacturing facilities

0
Continents with manufacturing facilities
0
R&D centres